Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
2.
Adv Exp Med Biol ; 860: 325-33, 2015.
Article in English | MEDLINE | ID: mdl-26303497

ABSTRACT

The aim of this study was to explore the role of BK channels in the hypoxic sensitivity of the in vivo murine carotid body (CB). Four strains of mice (DBA/2J, A/J, BKα1 knockout and BKα1 wild type - FVB background) were used. The mice were anesthetized, paralyzed and mechanically ventilated (PaCO(2) ~ 35 mmHg, PO(2) > 300 mmHg). We measured carotid sinus nerve (CSN) activity during three gas challenges (F(I)O(2): 0.21, 0.15 and 0.10). CSN activity was analyzed with time-variant spectral analysis with frequency domain conversion (Fast Fourier Transforms). Afferent CSN activity increased with lowering F(I)O(2) in the DBA/2J, BKKO and BKWT mice with the most robust response in 600-800 frequencies. No substantial changes were observed in the A/J mice. Although maximal neural output was similar between the BKKO and BKWT mice, the BKWT had a higher early response compared to BKKO. Thus, BK channels may play a role in the initial response of the CB to hypoxia. The contribution of BKß subunits or the importance of frequency specific responses was unable to be determined by the current study.


Subject(s)
Carotid Body/physiology , Carotid Sinus/innervation , Potassium Channels, Calcium-Activated/physiology , Animals , Hypoxia/physiopathology , Mice , Mice, Inbred DBA
3.
Diabetologia ; 54(6): 1350-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21369819

ABSTRACT

AIMS/HYPOTHESIS: In populations of East Asian descent, we performed a replication study of loci previously identified in populations of European descent as being associated with obesity measures such as BMI and type 2 diabetes. METHODS: We genotyped 14 single nucleotide polymorphisms (SNPs) from 13 candidate loci that had previously been identified by genome-wide association meta-analyses for obesity measures in Europeans. Genotyping was done in 18,264 participants from two general Japanese populations. For SNPs showing an obesity association in Japanese individuals, we further examined diabetes associations in up to 6,781 cases and 7,307 controls from a subset of the original, as well as from additional populations. RESULTS: Significant obesity associations (p < 0.1 two-tailed, concordant direction with previous reports) were replicated for 11 SNPs from the following ten loci in Japanese participants: SEC16B, TMEM18, GNPDA2, BDNF, MTCH2, BCDIN3D-FAIM2, SH2B1-ATP2A1, FTO, MC4R and KCTD15. The strongest effect was observed at TMEM18 rs4854344 (p = 7.1 × 10(-7) for BMI). Among the 11 SNPs showing significant obesity association, six were also associated with diabetes (OR 1.05-1.17; p = 0.04-2.4 × 10(-7)) after adjustment for BMI in the Japanese. When meta-analysed with data from the previous reports, the BMI-adjusted diabetes association was found to be highly significant for the FTO locus in East Asians (OR 1.13; 95% CI 1.09-1.18; p = 7.8 × 10(-10)) with substantial inter-ethnic heterogeneity (p = 0.003). CONCLUSIONS/INTERPRETATION: We confirmed that ten candidate loci are associated with obesity measures in the general Japanese populations. Six (of ten) loci exert diabetogenic effects in the Japanese, although relatively modest in size, and independently of increased adiposity.


Subject(s)
Asian People/genetics , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/genetics , Genetic Predisposition to Disease/genetics , Obesity/epidemiology , Obesity/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Asian People/ethnology , Body Mass Index , Brain-Derived Neurotrophic Factor/genetics , Case-Control Studies , Comorbidity , Diabetes Mellitus, Type 2/ethnology , Female , Genetic Predisposition to Disease/ethnology , Genotype , Humans , Japan , Male , Membrane Proteins/genetics , Membrane Transport Proteins/genetics , Middle Aged , Mitochondrial Membrane Transport Proteins , Mitochondrial Proteins/genetics , Obesity/ethnology
4.
Diabetologia ; 53(2): 299-308, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19937311

ABSTRACT

AIMS/HYPOTHESIS: To test fasting glucose association at four loci recently identified or verified by genome-wide association (GWA) studies of European populations, we performed a replication study in two Asian populations. METHODS: We genotyped five common variants previously reported in Europeans: rs1799884 (GCK), rs780094 (GCKR), rs560887 (G6PC2-ABCB11) and both rs1387153 and rs10830963 (MTNR1B) in the general Japanese (n = 4,813) and Sri Lankan (n = 2,319) populations. To identify novel variants, we further examined genetic associations near each locus by using GWA scan data on 776 non-diabetic Japanese samples. RESULTS: Fasting glucose association was replicated for the five single nucleotide polymorphisms (SNPs) at p < 0.05 (one-tailed test) in South Asians (Sri Lankan) as well as in East Asians (Japanese). In fine-mapping by GWA scan data, we identified in the G6PC2-ABCB11 region a novel SNP, rs3755157, with significant association in Japanese (p = 2.6 x 10(-8)) and Sri Lankan (p = 0.001) populations. The strength of association was more prominent at rs3755157 than that of the original SNP rs560887, with allelic heterogeneity detected between the SNPs. On analysing the cumulative effect of associated SNPs, we found the per-allele gradients (beta = 0.055 and 0.069 mmol/l in Japanese and Sri Lankans, respectively) to be almost equivalent to those reported in Europeans. CONCLUSIONS/INTERPRETATION: Fasting glucose association at four tested loci was proven to be replicable across ethnic groups. Despite this overall consistency, ethnic diversity in the pattern and strength of linkage disequilibrium certainly exists and can help to appreciably reduce potential causal variants after GWA studies.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Adaptor Proteins, Signal Transducing/genetics , Asian People/genetics , Blood Glucose/metabolism , Fasting/physiology , Genetic Variation , Glucose-6-Phosphatase/genetics , Polymorphism, Single Nucleotide , Protein Serine-Threonine Kinases/genetics , Receptor, Melatonin, MT2/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Alleles , Chromosome Mapping/methods , Ethnicity/genetics , Germinal Center Kinases , Haplotypes/genetics , Humans , Japan , Regression Analysis , Sri Lanka
5.
Neuroscience ; 141(2): 907-915, 2006 Aug 25.
Article in English | MEDLINE | ID: mdl-16797130

ABSTRACT

The present study was designed to clarify an intensity-dependent effect of prenatal stress on the morphological development of hippocampal neurons in rats. In addition, the involvement of receptors for glucocorticoids, i.e. mineralocorticoid receptors and glucocorticoid receptors, in stress-induced changes in the morphology of hippocampal neurons was examined by an in vitro pharmacological approach. The effects of mild prenatal stress on neurogenesis and long-term potentiation in the hippocampus were also investigated in adult offspring. Prenatal stress affected the morphological development of the hippocampus in an intensity-dependent manner. Short-lasting, mild prenatal stress enhanced neonatal neurogenesis and differentiation of processes of hippocampal neurons, whereas long-lasting, severe stress impaired their morphology. Mineralocorticoid receptor was found to mediate enhancement of neurogenesis and differentiation of processes of cultured hippocampal neurons. In contrast, glucocorticoid receptor was involved in the suppression of their morphology. Short-lasting, mild prenatal stress, which has previously been shown to enhance learning performance in adult offspring, facilitated neurogenesis and long-term potentiation in the adult hippocampus. These findings suggest that prenatal stress has enhancing and suppressing effects on the development of hippocampal neurons depending on intensity, and that mineralocorticoid receptors and glucocorticoid receptors contribute to stress-induced morphological changes.


Subject(s)
Cell Differentiation/physiology , Hippocampus/pathology , Neurons/pathology , Prenatal Exposure Delayed Effects/pathology , Stress, Physiological/pathology , Animals , Bromodeoxyuridine/metabolism , Cell Size/drug effects , Cells, Cultured , Electric Stimulation/methods , Embryo, Mammalian , Female , Glucocorticoids/pharmacology , Hippocampus/embryology , Hippocampus/physiopathology , Immunohistochemistry/methods , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Long-Term Potentiation/radiation effects , Microtubule-Associated Proteins/metabolism , Neurons/drug effects , Neurons/physiology , Neurons/ultrastructure , Phosphopyruvate Hydratase/metabolism , Pregnancy , Rats , Rats, Sprague-Dawley , Silver Staining/methods , Time Factors , Tubulin/metabolism
6.
Acta Anaesthesiol Scand ; 50(3): 364-7, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16480472

ABSTRACT

BACKGROUND: Subarachnoid blockade with local anesthetics induces respiratory depression. Although the addition of fentanyl to bupivacaine has become popular in subarachnoid blockade for Cesarean section, there is no information on the effect of intrathecal fentanyl on maternal spirometric respiratory function in parturients undergoing Cesarean section. METHODS: We tested the effect of the addition of intrathecal fentanyl to hyperbaric bupivacaine on maternal spirometric performance in 40 consenting parturients undergoing Cesarean section. The parturients were randomized into two groups: those receiving 2.0 ml of hyperbaric bupivacaine 0.5% and 0.4 ml of saline intrathecally and those receiving 2.0 ml of hyperbaric bupivacaine and 0.4 ml of fentanyl (20 microg) intrathecally. We performed spirometry on arriving at the operation room and 15 min after subarachnoid blockade. RESULTS: Subarachnoid blockade with bupivacaine significantly decreased the peak expiratory flow rate, but did not induce significant changes in vital capacity and forced vital capacity. The addition of intrathecal fentanyl to bupivacaine improved the quality of subarachnoid blockade, but did not lead to a deterioration in respiratory function compared with intrathecal bupivacaine alone. CONCLUSIONS: The addition of intrathecal fentanyl to hyperbaric bupivacaine did not lead to a deterioration in maternal spirometric respiratory function in parturients undergoing Cesarean section.


Subject(s)
Anesthesia, Obstetrical , Anesthesia, Spinal , Bupivacaine/administration & dosage , Fentanyl/administration & dosage , Respiration/drug effects , Adult , Cesarean Section , Female , Humans , Pregnancy , Vital Capacity/drug effects
7.
Neuroscience ; 118(2): 409-15, 2003.
Article in English | MEDLINE | ID: mdl-12699777

ABSTRACT

This study investigates whether maternal stress during pregnancy induces maternal and fetal hypothalamic paraventricular nucleus (PVN) neuronal activation and the effects of maternal stress on fetal hypothalamic and PVN brain-derived neurotrophic factor (BDNF) expression. Pregnant rats were exposed to three types of maternal stress with varying severity (restraint, forced walking and immobilization) for 30 min on gestational day 21. Severity of stress was assessed by measurement of maternal plasma corticosterone 30 min following the stimulus. Maternal plasma corticosterone increased in each stress response group (immobilization>forced walking>restraint). Further, the expression of Fos protein, a marker of neuronal activation, increased in the fetal and maternal PVN in direct relation to the severity of stress treatments. Forced walking and immobilized stress, but not restraint stress, significantly increased BDNF expression in the fetal hypothalamus.These findings suggest that the fetal hypothalamic-pituitary-adrenal (HPA) response following maternal stress mirrors maternal HPA activation. In addition, BDNF may play a role in protecting fetal brain neurons from damage caused by severe stress.


Subject(s)
Maternal-Fetal Exchange , Paraventricular Hypothalamic Nucleus/embryology , Paraventricular Hypothalamic Nucleus/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Stress, Physiological/metabolism , Animals , Blotting, Western , Brain-Derived Neurotrophic Factor/metabolism , Cell Count , Corticosterone/blood , Female , Fetus/metabolism , Immobilization , Immunohistochemistry , Male , Pregnancy , Rats , Restraint, Physical/methods , Walking
8.
Eur J Cancer ; 38(9): 1271-7, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12044515

ABSTRACT

The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. In an in vitro study, CDHP did not influence cell proliferation by itself. However, CDHP did inhibit 5-fluorouracil (5-FU) degradation and enhanced 5-FU cytotoxicity in a concentration-dependent manner in two human tumour cell lines (MIAPaCa-2 and HuTu80) with relatively high basal DPD activity. CDHP exhibited a maximum effect at a molar ratio (CDHP:5-FU) of more than 0.2. However, CDHP did not have any effect on 5-FU cytotoxicity in the CAL27 tumour cell line, which has a relatively low basal DPD activity, even at concentrations where the DPD activity is almost completely inhibited. In an in vivo study, the maximal tolerable doses (MTD) of tegafur (FT) and a combination of FT and CDHP at a molar ratio of 1:0.4 (FT/CDHP) for nude mice were determined by oral administration for 14 consecutive days. After a single oral administration of either FT or FT/CDHP at the MTD, the 5-FU serum concentration-time profiles were almost the same for both treatment strategies. When nude mice bearing subcutaneous (s.c.) MIAPaCa-2 cells were treated with either FT or FT/CDHP at the MTD, the FT/CDHP treatment showed a significantly higher antitumour effect than the FT treatment (tumour growth inhibition: FT/CDHP, 51+/-12%; FT, 21+/-25%; P<0.05). However, the host-body weight suppression induced by FT/CDHP and FT was equivalent. These findings suggest that the combination of fluoropyrimidine and CDHP for the treatment of tumours with a high basal DPD elicits a greater antitumour effect than treatment with fluoropyrimidines alone and we suggest that CDHP inhibits the degradation of 5-FU in the tumour.


Subject(s)
Fluorouracil/therapeutic use , Oxidoreductases/antagonists & inhibitors , Pancreatic Neoplasms/drug therapy , Pyridines/therapeutic use , Animals , Dihydrouracil Dehydrogenase (NADP) , Drug Interactions , Maximum Allowable Concentration , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Pancreatic Neoplasms/enzymology , Tumor Cells, Cultured
9.
Eur J Cancer ; 37(13): 1681-7, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11527696

ABSTRACT

A human tumour sub-line resistant to 5-fluorouracil (5-FU) was established by once a day and every 5, with at least 50 administrations of 5-FU to KM12C human colorectal xenografts in nude mice. KM12C tumours treated with 5-FU showed less sensitivity to 5-FU with an inhibition rate (IR) of 7.9%, while non-treated tumours were highly sensitive to 5-FU with an IR of 81.8%. To clarify the mechanism of 5-FU-resistance, the activities of various enzymes and gene expressions involved in the metabolism of 5-FU in both parental and 5-FU-treated KM12C tumours were measured. A 2- to 3-fold increase in thymidylate synthase (TS) activity and 4- to 5-fold decrease in ribonucleotide reductase (RNR) activity were observed in 5-FU-resistant KM12C tumours, while the activities of orotate phosphoribosyltransferase (OPRT) thymidine and uridine phosphorylases (TP,UP) and thymidine kinase (TK) were not markedly changed as a consequence of repeated treatment of KM12C tumours with 5-FU. The expression of TS mRNA was also amplified in accordance with the increased TS activity in a 5-FU-treated tumour sub-line (KM12C/5-FU) compared with that in parental tumours, but changed expressions of both RNR-R1 and RNA-R2 mRNA could not be detected in the 5-FU-resistant tumour sub-line compared with the parental tumours, suggesting possible post-transcriptional regulation of RNR. Moreover, RNR, in addition to TS and OPRT, seemed to be related to the inherent insensitivity to 5-FU in human cancer xenografts. From these results, it may be concluded that RNR activity is one of the acquired or inherent resistant factors, including TS, to 5-FU in human cancer xenografts in vivo.


Subject(s)
Colorectal Neoplasms/drug therapy , Drug Resistance, Neoplasm/physiology , Fluorouracil/therapeutic use , Ribonucleotide Reductases/metabolism , Thymidylate Synthase/metabolism , Animals , Blotting, Western , Colorectal Neoplasms/enzymology , Fluorouracil/metabolism , Humans , Mice , Mice, Nude , Neoplasm Transplantation , RNA, Messenger/metabolism , Transplantation, Heterologous
10.
Neuroscience ; 103(2): 301-7, 2001.
Article in English | MEDLINE | ID: mdl-11246145

ABSTRACT

The present study was designed to investigate whether mild stress during pregnancy affects offspring behaviors, including learning performance. Prenatal stress was induced by short-lasting, mild restraint stress, which had previously been shown to facilitate the morphological development of fetal brain neurons. Adult offspring whose dams had been restrained in a small cage for 30min daily from gestation day 15 to 17 showed enhanced active avoidance and radial maze learning performance. In addition, the prenatally stressed rats showed weaker emotional responses than unstressed control, as indicated by decreases both in ambulation upon initial exposure to an open field and in Fos expression in the amygdala induced by physical stress. The observed effects of prenatal stress on learning performance and emotional behavior were attenuated by foster rearing by unstressed dams. Fos expression in the hypothalamic paraventricular nucleus following physical stress and corticosterone secretion during physical and psychological stress did not differ between the prenatally stressed and unstressed control rats. From these results we suggest that mild prenatal stress facilitates learning performance in the adult offspring. The enhancement of learning performance appears to be accompanied by reduced emotionality, but not by any apparent alterations in hypothalamic-pituitary-adrenal responses. In addition, the observation of differential behaviors in the adopted and non-adopted animals supports the notion that the postnatal environment modifies the behavioral effects of prenatal stress.


Subject(s)
Behavior, Animal/physiology , Brain/physiology , Maze Learning/physiology , Stress, Psychological/physiopathology , Amygdala/metabolism , Animals , Avoidance Learning/physiology , Brain/growth & development , Corticosterone/blood , Emotions/physiology , Exploratory Behavior/physiology , Female , Male , Maternal Behavior/physiology , Paraventricular Hypothalamic Nucleus/metabolism , Pregnancy , Proto-Oncogene Proteins c-fos/metabolism , Rats , Space Perception/physiology
11.
Jpn J Cancer Res ; 92(3): 343-51, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11267946

ABSTRACT

We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside antimetabolite 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106). The cytotoxicity of TAS-106 in vitro against human tumors was evaluated at three drug exposure periods. TAS-106 exhibited fairly potent cytotoxicity even with 4 h exposure, and nearly equivalent and sufficiently potent cytotoxicity with 24 and 72 h exposures. These results suggest that long-term exposure to TAS-106 will not be required to achieve maximal cytotoxicity. The antitumor activity of TAS-106 in vivo was compared in nude rat models bearing human tumors on three administration schedules, once weekly, 3 times weekly, and 5 times weekly for 2 or 4 consecutive weeks. TAS-106 showed strong antitumor activity without serious toxicity on all three schedules, but the antitumor activity showed no obvious schedule-dependency in these models. When tumor-bearing nude rats were given a single i.v. dose of [(3)H]TAS-106, tumor tissue radioactivity tended to remain high for longer periods of time as compared to the radioactivity in various normal tissues. Furthermore, when the metabolism of TAS-106 in the tumor was examined, it was found that TAS-106 nucleotides (including the active metabolite, the triphosphate of TAS-106) were retained at high concentrations for prolonged periods. These pharmacodynamic features of TAS-106 may explain the strong antitumor activity without serious toxicity, observed on intermittent administration schedules, in nude rat models with human tumors. We therefore consider TAS-106 to be a promising compound which merits further investigation in patients with solid tumors.


Subject(s)
Antimetabolites, Antineoplastic/pharmacokinetics , Antimetabolites, Antineoplastic/therapeutic use , Cell Survival/drug effects , Cytidine/pharmacokinetics , Cytidine/therapeutic use , Lung Neoplasms/drug therapy , Stomach Neoplasms/drug therapy , Animals , Antimetabolites, Antineoplastic/toxicity , Breast Neoplasms , Colonic Neoplasms , Cytidine/analogs & derivatives , Cytidine/toxicity , Female , Humans , Male , Pancreatic Neoplasms , Rats , Rats, Inbred F344 , Rats, Nude , Tissue Distribution , Transplantation, Heterologous , Tumor Cells, Cultured
12.
Br J Dermatol ; 143(4): 728-32, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11069448

ABSTRACT

BACKGROUND: Elafin, an elastase inhibitor produced by keratinocytes, is overexpressed in the subcorneal region of skin affected by psoriasis, a major feature of which is epidermal infiltration by neutrophil leucocytes. OBJECTIVES: We studied the expression of elafin in the epidermis in other skin disorders characterized by dermal neutrophil infiltration and in skin disorders with dermal lymphocyte infiltration. PATIENTS/METHODS: We examined biopsies from the lesional skin of patients with Behçet's syndrome, Sweet's syndrome, pyoderma gangrenosum, cutaneous allergic vasculitis and acute bacterial infection (cellulitis), and from the skin of patients with chronic prurigo, discoid lupus erythematosus and psoriasis. We performed in vitro experiments using cultured keratinocytes treated with mediators such as interleukin (IL)-1 beta, tumour necrosis factor (TNF)-alpha, IL-6, neutrophil elastase and interferon (IFN)-gamma. RESULTS: Anti-elafin antibody showed a strong reaction with the subcorneal region of the epidermis in patients with Behçet's syndrome, Sweet's syndrome, pyoderma gangrenosum, cutaneous allergic vasculitis and acute bacterial infection (cellulitis), but showed no reaction in skin from patients with dermal lymphocyte infiltration such as is seen in chronic prurigo and discoid lupus erythematosus. The in vitro experiments demonstrated that treatment with IL-1 beta and TNF-alpha resulted in 2.6-fold and 4-fold stimulation of elafin secretion, respectively, whereas IL-6, neutrophil elastase and IFN-gamma caused no significant changes in elafin release. CONCLUSIONS: These results suggest that inflammatory mediators such as IL-1 beta or TNF-alpha secreted by dermal neutrophils may be involved in overexpression of elafin in keratinocytes; this could protect the epidermis from degradation by dermal neutrophil infiltration.


Subject(s)
Epidermis/metabolism , Neutrophils/physiology , Proteins/metabolism , Skin Diseases/metabolism , Cell Culture Techniques , Epidermis/pathology , Gene Expression Regulation , Humans , Interleukin-1/pharmacology , Keratinocytes/metabolism , Proteinase Inhibitory Proteins, Secretory , Proteins/genetics , RNA, Messenger/genetics , Skin Diseases/pathology , Tumor Necrosis Factor-alpha/pharmacology
13.
Acta Derm Venereol ; 80(2): 102-5, 2000.
Article in English | MEDLINE | ID: mdl-10877128

ABSTRACT

The levels of proelafin peptides in the sera of patients with pustulosis palmoplantaris, a unique type of localized pustular psoriasis, and generalized pustular psoriasis were determined by competitive enzyme-linked immunosorbent assays using antibodies against synthetic proelafin polypeptides corresponding to the elastase inhibitor (elafin) and transglutaminase substrate domains. The sera of patients with pustulosis palmoplantaris (9 cases) exhibited a normal range of proelafin peptide levels. The sera of patients with generalized pustular psoriasis (3 cases) showed high titres of proelafin peptide. There were no large differences in the titres between the 2 antibodies. The antibodies for 2 different domains of proelafin showed a similar immunoreactivity for the non-pustular region of the epidermis in all pustulosis palmoplantaris tested. The results indicate that serum proelafin peptides in pustular psoriasis may depend on the extent of the involved area, and that proelafin peptide level in pustulosis palmoplantaris remains normal despite enhanced local expression in the lesional skin. Since the skin lesions of patients with pustulosis palmoplantaris are limited to the palms and soles, enhanced expression of proelafin in the lesional skin may not lead to elevation of proelafin peptides in the serum.


Subject(s)
Proteins/pharmacokinetics , Psoriasis/blood , Psoriasis/drug therapy , Serine Proteinase Inhibitors/blood , Adult , Biomarkers/analysis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Male , Middle Aged , Proteinase Inhibitory Proteins, Secretory , Psoriasis/pathology , Reference Values , Sensitivity and Specificity
14.
J Dermatol ; 27(5): 333-6, 2000 May.
Article in English | MEDLINE | ID: mdl-10875201

ABSTRACT

Relatively little is known about the incidence of Spitz nevus on palmar surfaces. This report places a case study in the context of the Japanese literature regarding the occurrence of Spitz nevus on palmar surfaces. Although the proportion of palms and soles in relation to the body surface is about 5%, the incidence of the Spitz nevus was 2%. The mean age at onset was 17.8 years, and all 4 cases were women. The clinical features were a black macule or flatly elevated small modules. The size of the lesions was relatively small, extending from 3.5 mm to 8.0 mm. Although the backs of the hands and insteps have almost the same area as the palms and soles, the incidence of onset in these regions was 6.3% (13 cases). We thus concluded that Spitz nevus tends to be rare on palms and soles.


Subject(s)
Hand Dermatoses/pathology , Nevus, Epithelioid and Spindle Cell/pathology , Skin Neoplasms/pathology , Child , Diagnosis, Differential , Female , Hand Dermatoses/epidemiology , Humans , Incidence , Japan/epidemiology , Nevus, Epithelioid and Spindle Cell/epidemiology , Skin Neoplasms/epidemiology
15.
Int J Mol Med ; 5(4): 357-62, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10719050

ABSTRACT

We evaluated the postoperative adjuvant chemotherapy by UFT using the primary tumor amputation-pulmonary metastasis model. When Lewis lung carcinoma (LLC) primary tumors on the hind foot pad grew palpable, they were amputated on two different days. In experiment (A) (earlier amputation model), micrometastases were detected on the day of amputation only by the histopathological examination. In the experiment (B) (later amputation model), nodules could be determined even by necropsy. Long-term (60-day) consecutive administration of UFT (22 mg/kg/day), which produced no body weight loss, markedly prolonged the survival period in experiment (A) (ILS: over 118%), 1 of the 15 mice being cured. UFT had a relatively weak but significant effect (67% of ILS) in schedule (B). Using the same model, we examined the inhibitory effect of UFT (2-week administration) on the number of metastatic nodules. A significant decrease of metastatic nodules was observed by UFT with both amputation schedules, but its effect was superior with schedule (A). In the same model using Colon 26 PMF-15, UFT markedly prolonged the survival period of mice (150% of ILS) and significantly decreased the metastatic nodules (86% inhibition). The dose of UFT used was relatively low, and did not significantly inhibit the growth of large tumors. However, the sensitivity to the micrometastases was high. These findings suggest that the postoperative adjuvant chemotherapy by the long-term consecutive administration of UFT would be effective for clinical cancer especially in curatively resected cases.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Lewis Lung/drug therapy , Colonic Neoplasms/drug therapy , Lung Neoplasms/drug therapy , Amputation, Surgical , Animals , Body Weight/drug effects , Carcinoma, Lewis Lung/mortality , Carcinoma, Lewis Lung/secondary , Chemotherapy, Adjuvant , Colonic Neoplasms/mortality , Colonic Neoplasms/secondary , Foot/surgery , Lung Neoplasms/mortality , Lung Neoplasms/secondary , Male , Mice , Mice, Inbred C57BL , Neoplasm Metastasis/drug therapy , Postoperative Period , Survival Rate , Tegafur/administration & dosage , Time Factors , Uracil/administration & dosage
16.
Cancer Chemother Pharmacol ; 45(2): 133-41, 2000.
Article in English | MEDLINE | ID: mdl-10663628

ABSTRACT

PURPOSE: We evaluated miproxifene phosphate (TAT-59) to elucidate its efficacy in antiestrogen therapy for breast cancer patients and to assess its tissue-selective estrogenic/antiestrogenic activity. METHODS: Using DP-TAT-59, a major and active metabolite of TAT-59, an in vitro cell growth inhibition test was performed. Antitumor activity was determined using TAT-59 against human tumor xenografts of the MCF-7 and the Br-10 cell lines and MCF-7-derived tamoxifen-resistant cell lines, R-27 and FST-1. The antitumor activity of DP-TAT-59 and DM-DP-TAT-59, major metabolites of TAT-59 found in human blood following a TAT-59 dose, was also examined after intravenous administration to experimental animals. The residual estrogenic activity of TAT-59, evaluated in terms of bone and lipid metabolism in ovariectomized rats, was then compared with that of tamoxifen. RESULTS: DP-TAT-59 significantly inhibited the proliferation of estrogen receptor-positive MCF-7 and T-47D tumor cells in the presence of 1 nM estradiol. TAT-59, given to mice bearing MCF-7 or Br-10 xenografts, at the dose level of 5 mg/kg, exerted a significant growth inhibitory effect that was stronger than that of tamoxifen. Moreover, R-27 and FST-1 tumors, which show a resistance to tamoxifen, responded strongly to TAT-59, suggesting that TAT-59 might be effective against tumors resistant to tamoxifen. The metabolites of TAT-59, DP-TAT-59 and DM-DP-TAT-59, showed similar antitumor activity. Both TAT-59 and tamoxifen suppressed the decrease in bone density and reduced the blood cholesterol levels in ovariectomized rats, suggesting that the estrogenic activity of TAT-59 is comparable to that of tamoxifen. CONCLUSIONS: On the basis of the above results, one may expect TAT-59 to become an effective drug in patients with tumors less sensitive to tamoxifen, while its estrogenic activity as determined by bone and lipid metabolism is similar to that of tamoxifen.


Subject(s)
Breast Neoplasms/pathology , Estrogen Antagonists/pharmacology , Tamoxifen/analogs & derivatives , Animals , Antineoplastic Agents, Hormonal/pharmacology , Cell Division/drug effects , Drug Screening Assays, Antitumor , Estradiol/pharmacology , Female , Humans , Lipid Metabolism , Mice , Mice, Inbred BALB C , Rats , Rats, Sprague-Dawley , Receptors, Estrogen/physiology , Tamoxifen/pharmacology , Transplantation, Heterologous , Tumor Cells, Cultured/drug effects
17.
Clin Exp Dermatol ; 24(3): 196-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10354179

ABSTRACT

Two cases of hyperthyroidism with hyperpigmentation are presented. In both cases, hyperpigmentation was seen on the lower extremities, most strikingly on the shins, backs of the feet and the nail bed. Histology of the pigmented skin showed basal melanosis and heavy deposition of haemosiderin around dermal capillaries and sweat glands. Treatment with mercazol in both cases resulted in no significant waning of pigmentation. Distribution of hyperpigmentation, haemosiderin deposition and poor response to the treatment may be characteristic features of the pigmentation caused by hyperthyroidism, and may represent differences from the pigmentation seen in Addison's disease.


Subject(s)
Hyperpigmentation/etiology , Hyperthyroidism/complications , Addison Disease/complications , Addison Disease/drug therapy , Addison Disease/pathology , Adult , Antithyroid Agents/therapeutic use , Hemosiderosis/drug therapy , Hemosiderosis/etiology , Hemosiderosis/pathology , Humans , Hyperpigmentation/drug therapy , Hyperpigmentation/pathology , Hyperthyroidism/drug therapy , Hyperthyroidism/pathology , Male , Melanosis/drug therapy , Melanosis/etiology , Melanosis/pathology , Methimazole/therapeutic use , Middle Aged , Sweat Gland Diseases/pathology
19.
Glia ; 25(3): 240-6, 1999 Feb 01.
Article in English | MEDLINE | ID: mdl-9932870

ABSTRACT

Aquaporin 4 (AQP4) is a predominant water channel protein in mammalian brains, localized in the astrocyte plasma membrane. The regulation of AQP4 is believed to be important for the homeostasis of water in the brain, but the AQP4 regulatory mechanisms are not yet known. In this study, we investigated the effect of a protein kinase C (PKC) activator on the expression of AQP4 mRNA in cultured rat astrocytes. Cultured rat astrocytes constitutively expressed AQP4 mRNA. Treatment of the cells with 0.1 microM of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA), an activator of PKC, caused a rapid decrease in AQP4 mRNA. This effect was time- and dose-dependent. The TPA-induced decrease in AQP4 mRNA was inhibited by a relatively specific PKC inhibitor, 1-(5-isoquinoline sulfonyl)-2-methylpiperazine (H7) in a dose-dependent manner. Moreover, prolonged treatment of the cells with TPA eliminated the subsequent decrease in AQP4 mRNA by TPA. These results strongly suggest that the TPA-induced decrease in AQP4 mRNA is mediated by PKC activation. To test whether the effect of TPA requires protein synthesis, astrocytes were pretreated with cycloheximide, an inhibitor of protein synthesis. Pretreatment of the cells with cycloheximide did not inhibit the decrease in AQP4 mRNA induced by TPA. To test whether the TPA-induced decrease in AQP4 was due to a decrease in the mRNA stability, we examined the effect of actinomycin D, an inhibitor of transcription, on TPA-treated cells. The stability of AQP4 mRNA was not decreased by the pretreatment of the cells with actinomycin D. The results suggest that AQP4 mRNA is inhibited by TPA via PKC activation without de novo protein synthesis, and that the inhibition of AQP4 mRNA could be at the transcriptional level.


Subject(s)
Aquaporins/drug effects , Aquaporins/genetics , Astrocytes/drug effects , Protein Kinase C/drug effects , RNA, Messenger/metabolism , Tetradecanoylphorbol Acetate/pharmacology , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Animals , Animals, Newborn , Aquaporin 4 , Aquaporins/biosynthesis , Astrocytes/metabolism , Cells, Cultured , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Dose-Response Relationship, Drug , Enzyme Activation , Gene Expression Regulation/drug effects , Protein Kinase C/biosynthesis , Protein Synthesis Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley
20.
Nephrol Dial Transplant ; 14 Suppl 1: 73-5, 1999.
Article in English | MEDLINE | ID: mdl-10048459

ABSTRACT

A cDNA encoding an Na+-Pi co-transporter, termed rat PiT-1, has now been isolated from rat parathyroid. Expression of rat PiT-1 in Xenopus oocytes revealed that it possesses Na+-dependent Pi co-transport activity. The amount of PiT-1 mRNA in the parathyroid of vitamin D-deficient rats was reduced compared with that in normal animals, and increased markedly after administration of 1,25-dihydroxyvitamin D3. Furthermore, the abundance of PiT-1 mRNA in the parathyroid was much greater in rats fed a low-Pi diet than in those fed a high-Pi diet. Thus, rat PiT-1 may contribute to the effects of Pi and vitamin D on parathyroid function.


Subject(s)
Carrier Proteins/metabolism , Parathyroid Glands/metabolism , Symporters , Animals , Calcitriol/pharmacology , Carrier Proteins/genetics , Cloning, Molecular , Diet , Phosphates/administration & dosage , Phosphates/pharmacology , RNA, Messenger/metabolism , Rats , Sodium-Phosphate Cotransporter Proteins , Sodium-Phosphate Cotransporter Proteins, Type III , Thyroid Gland/metabolism , Vitamin D Deficiency/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...